Abstract: The present invention relates to obesity control by regulating the expression level of TREK1.

Abstract: A high-speed device, for inspecting a large area of an object, which includes: a terahertz wave generation portion configured to generate a terahertz wave; a ring beam forming portion configured to form a ring beam by using the terahertz wave incident from the terahertz wave generation portion; a rotary mirror configured to reflect the ring beam formed by the ring beam forming portion while rotating to allow the ring beam to be incident on an inspection target object; and a detector configured to detect a ring beam generated from the inspection target object.

Abstract: The present invention relates to a composition comprising as an active ingredient a strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity; and to a food composition and a health functional food each comprising the active ingredient. The strain having excellent ability to produce formic acid according to the present invention not only has effects of reducing body weight and inhibiting fat accumulation in organs, but also has activity to effectively lower blood triglyceride and cholesterol levels, and therefore, the composition comprising the strain as an active ingredient can be favorably used as a composition capable of preventing/alleviating or treating obesity or metabolic syndromes caused by obesity. Therefore, the strain having excellent ability to produce formic acid according to the present invention can be favorably used as a material for a medical product or health food.

Abstract: The present disclosure relates to novel Lactobacillus curvatus WIKIM55 isolated from kimchi, and a composition containing the same. The Lactobacillus curvatus WIKIM55 according to the present disclosure is a probiotic having activities of promoting hair growth and can be diversely applied for intestinal regulation and promotion of hair growth in humans or animals.

Abstract: There is provided a paper-based colorimetric sensor kit for quickly and simply diagnosing mercury in situ with a naked eye. The paper-based colorimetric sensor kit includes: a circular template for rolling circle amplification (RCA); a primer that does not hybridize to the circular template when a mercury ion is bonded to a primer that hybridizes to the circular template; a DNA polymerase; a sensing material kit including a nanoparticle probe labeled to a DNA coil formed in the circular template for RCA; and a radial chromatography paper.

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition, which include phloroglucinol active ingredient, for preventing, treating, or ameliorating somnipathy and suppressing intolerance to, alleviating, or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor. The pharmaceutical composition and the food composition rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, and neither cause side effects nor intolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration.

Abstract: The present invention relates to a strain having liver function improving activity, and a use thereof. Specifically, the present invention relates to a health food composition for improving liver function and a pharmaceutical composition for improving liver function, which contain, as an active ingredient, one or more strains selected from the group consisting of a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, and a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a lysate thereof or a culture product thereof.

Abstract: The present invention relates to a composition for inhibiting non-fluorescent advanced glycation end products, and a use thereof. More specifically, the present invention relates to: a composition for inhibiting non-fluorescent advanced glycation end products, comprising one or more strains selected from the group consisting of Lactobacillus sp. strains, Lactococcus sp. strains, Enterococcus sp. strains, Bifidobacterium sp. strains, Bacillus sp. strains, Saccharomyces sp. strains, Pediococcus sp. strains, and Leuconostoc sp. strains; and a food composition, a pharmaceutical composition, a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, which have an activity of reducing non-fluorescent advanced glycation end products and comprise the composition. In addition, the present invention relates to a method for producing a non-fluorescent advanced glycation end product inhibitor and a method for inhibiting non-fluorescent advanced glycation end products.

Abstract: The present invention relates to novel Weissella hellenica WiKim0103 isolated from Kimchi and a composition comprising the same or its use. The present invention provides a method for prevention, improvement and treatment of inflammation, obesity or fatty liver disease of a subject by administering the novel Weissella hellenica WiKim0103 isolated from Kimchi or a composition comprising thereof. The Weissella hellenica WiKim0103 according to the present invention shows an inhibitory effect for fatty liver production by inhibiting fat accumulation in liver cells and reducing expression of fatty liver-related genes, and thus it may be variously utilized for uses in prevention, improvement and treatment of inflammation, obesity or fatty liver disease.

Abstract: The present disclosure relates to a composition for discriminating the species Lactobacillus acidophilus, which enables microorganisms belonging to the species Lactobacillus acidophilus to be discriminated, detected and identified simply, quickly and accurately from a target sample. Therefore, the present disclosure can be effectively used in the development of fermented milk, baby food, dairy products, livestock feed, cosmetics, health supplements, drugs for intestinal disorders, raw materials, etc. using the Lactobacillus acidophilus sp. strain.

Abstract: The present disclosure relates to novel Lactobacillus sakei WIKIM0109 isolated from kimchi and a composition containing the same. The Lactobacillus sakei WIKIM0109 according to the present disclosure is a lactic acid bacterium having an activity of inhibiting IgG and IgG2a production in blood and an activity of inhibiting IFN-?, IL-17 and TNF-? production, and can be used in various applications, such as for preventing and ameliorating arthritis or improving intestinal regulation in human or animals.

Abstract: The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression.

Abstract: The present disclosure relates to a composition for preventing, alleviating or treating a neurodegenerative disease, which contains Pediococcus inopinatus as an active ingredient. The Pediococcus inopinatus strain according to the present disclosure can suppress neuroinflammation and can also alleviate the symptoms of ataxia in an animal model of Parkinson's disease and, thus, can be utilized for the prevention, alleviation and treatment of various neurodegenerative diseases including Parkinson's disease.

Abstract: The present invention relates to a novel Lactobacillus fermentum WiKim0102 (Accession No. KCCM12356P) isolated from kimchi and a composition comprising the same as an active ingredient. Lactobacillus fermentum WiKim0102 according to the present invention shows excellent anti-cancer activity in conventional animal models and animal models in which a human cancer cell is transplanted, and therefore it can be usefully used as a composition in use of treatment, prevention or improvement of cancer of humans or animals.

Abstract: The present disclosure relates to a composition for preventing, alleviating or treating depression or anxiety disorder, which contains Lactobacillus sakei as an active ingredient. The Lactobacillus sakei strain according to the present disclosure can be used to prevent, alleviate or treat a mental disorder such as depression or anxiety disorder.

Abstract: The present invention, which is a food composition for alleviating diabetes that contains Schisandra chinensis fruit water and bean juice as active ingredients, has a high inhibitory activity against ?-glucosidase and prevents a rise of the blood sugar after meals, thereby alleviating diabetes. The food composition for alleviating diabetes can be prepared in different forms, such as soy milk, powdered soy milk, other forms of soy milk, or processed bean curd, and used in the preparation of health functional foods for blood sugar control or foods for diabetics according to the Special Purpose Foods of the general foods. In addition, the food composition for alleviating diabetes according to the present invention, when further containing a saccharified material of grain, maintains viscosity similar to that of regular soy milk by preventing agglomeration of the liquid soy milk and improves sensory properties, so it can be suitable for use in beverages such as soy milk or other forms of soy milk.

Abstract: A novel Lactobacillus paracasei AO356 strain according to the present disclosure, which is a strain isolated from the human body, has high stability, exhibits the activity of inhibiting adipogenic differentiation in vitro and inducing the differentiation of M1 and M0 macrophages into M2 macrophages, and has excellent activity of alleviating, preventing, or treating obesity, such as the activity of reducing body weight and a reduction in blood lipid concentration through the browning of white fat in animal experiments. Thus, the novel strain of the present disclosure has a low possibility of causing side effects, and therefore, unlike conventional diet functional foods or drugs, which have side effect problems, a diet effect can be exhibited without controlling the dose thereof. Accordingly, the novel strain can be used as a pharmaceutical composition for treating or preventing obesity or a food composition for alleviating or preventing obesity.

Abstract: The present invention relates to a novel Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) isolated from kimchi and a composition comprising the same as an active ingredient. Lactobacillus sakei WIKIM30 according to the present invention shows excellent anti-cancer activity in animal models in which a cancer cell is transplanted and cancer cell lines, and therefore it can be usefully used as a composition in use of treatment, prevention or improvement of cancer of humans or animals.

Abstract: Provided is a novel Lactobacillus acidophilus YTI strain (deposition number: KCCM 11808P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus acidophilus comprising the novel strain.

Abstract: The present invention relates to novel Leuconostoc citreum WiKim0104 isolated from Kimchi and a composition comprising the same or its use. The present invention provides a method for prevention, improvement and treatment of inflammation, obesity or fatty liver disease of a subject by administering the novel Leuconostoc citreum WiKim0104 isolated from Kimchi or a composition comprising thereof. The Leuconostoc citreum WiKim0104 according to the present invention shows an inhibitory effect for fatty liver production by inhibiting fat accumulation in liver cells and reducing expression of fatty liver-related genes, and thus it may be variously utilized for uses in prevention, improvement and treatment of inflammation, obesity or fatty liver disease.